Share This Page
Drug Price Trends for NDC 72888-0156
✉ Email this page to a colleague
Average Pharmacy Cost for 72888-0156
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARBIDOPA-LEVO ER 50-200 TAB | 72888-0156-01 | 0.20523 | EACH | 2025-04-23 |
| CARBIDOPA-LEVO ER 50-200 TAB | 72888-0156-30 | 0.20523 | EACH | 2025-04-23 |
| CARBIDOPA-LEVO ER 50-200 TAB | 72888-0156-30 | 0.20839 | EACH | 2025-03-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72888-0156
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| No data available in table | |||||||
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Carbidopa/Levodopa (NDC 72888-0156)
The global pharmaceutical landscape for Parkinson’s disease (PD) treatments has undergone significant transformation in recent years, driven by demographic shifts, technological advancements, and evolving therapeutic paradigms. Carbidopa/levodopa, a cornerstone therapy for PD, remains a critical component of symptom management. This report provides a comprehensive analysis of the market dynamics, pricing trends, and future projections for the formulation associated with National Drug Code (NDC) 72888-0156, a combination product of carbidopa and levodopa.
Current Market Landscape for Carbidopa/Levodopa
Role in Parkinson’s Disease Management
Carbidopa/levodopa is the gold-standard treatment for PD, addressing motor symptoms such as tremors, rigidity, and bradykinesia by replenishing dopamine levels in the brain[15][17]. The combination mitigates peripheral dopamine conversion, enhancing central nervous system delivery and reducing side effects[15]. As a generic formulation, it is widely prescribed due to its efficacy, affordability, and established safety profile compared to newer branded therapies[16].
Market Size and Growth Drivers
The global levodopa market was valued at $1.7 billion in 2022 and is projected to reach $2.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.1%[15]. This growth is fueled by:
- Aging Populations: PD prevalence increases with age, and the global population over 60 is expanding rapidly[15][17].
- Cost-Effectiveness: Generic formulations like NDC 72888-0156 dominate due to lower annual costs of therapy (ACOT) compared to novel biologics or advanced delivery systems[10][16].
- Therapeutic Necessity: Despite the development of adjunctive therapies, levodopa remains irreplaceable for symptom control[16][18].
Pricing Analysis for NDC 72888-0156
Current Pricing Trends
As of 2024–2025, the unit price for NDC 72888-0156 (carbidopa/levodopa 25–100 mg extended-release tablets) ranges between $0.94 and $1.81 per tablet, depending on package size and vendor[11]. For example:
- 100-count packages: Priced at $93.80–$180.50, translating to $0.94–$1.81 per tablet[11].
- 30-count packages: Priced at $28.14, or $0.94 per tablet[11].
These prices reflect competitive pricing strategies among generic manufacturers such as Advagen Pharma, Mylan, and Accord Healthcare[11].
Factors Influencing Price Variability
- Volume Discounts: Larger packages (e.g., 500–1,000 tablets) reduce per-unit costs by 15–20%[11].
- Manufacturer Competition: Multiple suppliers, including SciGen Pharmaceuticals and Westminster Pharmaceuticals, drive price compression[11].
- Regulatory and Inflationary Pressures: The U.S. pharmaceutical market is projected to experience 3.81% annual price inflation in 2025, impacting generic drug pricing[13].
Future Price Projections
Short-Term Outlook (2025–2027)
Prices for NDC 72888-0156 are expected to rise modestly, aligning with broader drug price inflation trends. Applying the projected 3.81% annual increase[13]:
- 2025: $1.81/tablet × 1.0381 = $1.88/tablet
- 2026: $1.88 × 1.0381 = $1.95/tablet
- 2027: $1.95 × 1.0381 = $2.03/tablet
Long-Term Outlook (2028–2032)
Beyond inflation, market forces will shape pricing:
- Pipeline Competition: Subcutaneous levodopa formulations (e.g., AbbVie’s ABBV-951) may capture market share but will likely target advanced PD patients, preserving demand for oral carbidopa/levodopa[16][18].
- Generic Saturation: Increased participation from manufacturers in emerging markets (e.g., Asia-Pacific) could stabilize prices despite inflation[15][18].
- Policy Interventions: U.S. price transparency initiatives and international reference pricing may constrain excessive price hikes[12].
By 2032, the per-tablet price is projected to reach $2.40–$2.60, assuming a 3.5–4.0% CAGR post-2027[13][15].
Market Opportunities and Challenges
Growth Opportunities
- Emerging Markets: Asia-Pacific, with its rapidly aging population, is anticipated to exhibit the highest CAGR (8.9%) in PD treatment demand[10][15].
- Formulation Innovations: Extended-release and combination products (e.g., carbidopa/levodopa/entacapone) could capture premium pricing segments[17].
Key Challenges
- Disease-Modifying Therapies: Monoclonal antibodies like prasinezumab (PRX-002) may disrupt the market if proven to slow PD progression[16][18].
- Adherence Issues: Pill burden and dosing frequency limit patient compliance, creating opportunities for alternative delivery systems[16].
Competitive Landscape
Major Manufacturers
- Advagen Pharma: Leading supplier of NDC 72888-0156, offering 100-, 500-, and 1,000-count packages[11].
- Mylan (Viatris): Competes with pricing at $0.99 per tablet[11].
- Accord Healthcare: Provides cost-competitive alternatives in Europe and North America[11].
Strategic Positioning
Generic manufacturers are leveraging economies of scale and vertical integration to maintain profitability amid price pressures. For instance, Advagen Pharma’s 1,000-count package ($734.37) achieves a 20% cost advantage over smaller lots[11].
Conclusion
The carbidopa/levodopa market, exemplified by NDC 72888-0156, is poised for steady growth driven by demographic trends and therapeutic indispensability. While price inflation and competitive pressures will modestly elevate costs, the drug’s foundational role in PD management ensures sustained demand. Stakeholders should monitor regulatory developments and pipeline advancements to navigate this evolving landscape effectively.
"The Parkinson’s disease market is expected to triple in sales by 2029, with carbidopa/levodopa remaining a cornerstone therapy despite emerging alternatives."
—GlobalData, 2025[10][16]
Key Takeaways
- NDC 72888-0156 prices will rise gradually, reaching $2.40–$2.60/tablet by 2032.
- The global levodopa market will grow at 6.1% CAGR, driven by aging populations and PD prevalence[15].
- Generic manufacturers must balance pricing strategies with inflationary and competitive pressures to maintain market share.
FAQs
1. Why is carbidopa combined with levodopa?
Carbidopa inhibits peripheral dopamine conversion, reducing side effects and enhancing central delivery[15].
2. How does NDC 72888-0156 compare to newer PD therapies?
It remains cost-effective for early-stage PD, while advanced therapies target refractory symptoms[16][18].
3. What regions show the highest growth potential?
Asia-Pacific, due to aging populations and improving healthcare access[10][15].
4. Will gene therapies replace carbidopa/levodopa?
Unlikely before 2035, as current pipelines focus on adjunctive use[10][16].
5. How does U.S. pricing compare internationally?
U.S. prices are 30–50% higher than in OECD countries, reflecting market dynamics[12].
References
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a401fe31-d51a-49d9-a062-c9d22088db56
- https://www.alliedmarketresearch.com/pharmaceutical-suppositories-market-A12350
- https://www.drugpatentwatch.com/p/drug-price/ndc/72888-0119
- https://www.drugpatentwatch.com/p/drug-price/ndc/72888-0060
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93b12089-3a0f-4b57-abb1-2429cf31995d
- https://www.databridgemarketresearch.com/reports/north-america-adalimumab-market
- https://www.mayoclinic.org/drugs-supplements/levorphanol-oral-route/description/drg-20074036
- https://www.clinicaltrialsarena.com/analyst-comment/schizophrenia-market-17bn-7mm-2031/
- https://www.findacode.com/code.php?set=NDC&c=72888-0156
- https://www.globenewswire.com/news-release/2025/03/05/3037571/28124/en/7MM-7-9-Bn-Parkinson-s-Disease-Market-Drug-Forecast-and-Market-Analysis-2023-2025-2033-Novel-Symptomatic-treatments-will-continue-to-shape-the-PD-market.html
- https://merztherapeutics.com/us/wp-content/uploads/sites/6/2024/11/Inbrija-VT-Long-Form-Q4-10.23.2024.pdf?x59393
- https://aspe.hhs.gov/sites/default/files/documents/bc582e25376d714694524a492fb15f36/international-prescription-drug-price-comparisons.pdf
- https://www.drugpatentwatch.com/p/drug-price/ndc/72888-0185
- https://www.researchandmarkets.com/reports/5314299/parkinsons-disease-global-drug-forecast-and
- https://www.alliedmarketresearch.com/levodopa-market-A213646
- https://www.europeanpharmaceuticalreview.com/news/160045/parkinsons-disease-market-sales-to-reach-11-5-billion-in-2029/
- https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
- https://www.zionmarketresearch.com/report/parkinsons-disease-treatment-market
More… ↓
